Potential benefits of melatonin in organ transplantation

A review

Eduardo Esteban-Zubero, Francisco Agustín García-Gil, Laura López-Pingarrón, Moisés Alejandro Alatorre-Jiménez, Pablo Iñigo-Gil, Dun Xian Tan, José Joaquín García, Russel J Reiter

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Organ transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemiareperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acid l-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.

Original languageEnglish (US)
Pages (from-to)R129-R146
JournalJournal of Endocrinology
Volume229
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Organ Transplantation
Melatonin
Graft Rejection
Antioxidants
5-Methoxytryptamine
Pancreas Transplantation
Free Radical Scavengers
Essential Amino Acids
Pineal Gland
Ants
Lung Transplantation
Otolaryngology
Tryptophan
Liver Transplantation
Kidney Transplantation
Placenta
Free Radicals
Testis
Ovary
Anti-Inflammatory Agents

Keywords

  • Graft failure
  • Ischemia-reperfusion injury
  • Melatonin
  • Organ transplantation
  • Preservation fluids

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Esteban-Zubero, E., García-Gil, F. A., López-Pingarrón, L., Alatorre-Jiménez, M. A., Iñigo-Gil, P., Tan, D. X., ... Reiter, R. J. (2016). Potential benefits of melatonin in organ transplantation: A review. Journal of Endocrinology, 229(3), R129-R146. https://doi.org/10.1530/JOE-16-0117

Potential benefits of melatonin in organ transplantation : A review. / Esteban-Zubero, Eduardo; García-Gil, Francisco Agustín; López-Pingarrón, Laura; Alatorre-Jiménez, Moisés Alejandro; Iñigo-Gil, Pablo; Tan, Dun Xian; García, José Joaquín; Reiter, Russel J.

In: Journal of Endocrinology, Vol. 229, No. 3, 2016, p. R129-R146.

Research output: Contribution to journalReview article

Esteban-Zubero, E, García-Gil, FA, López-Pingarrón, L, Alatorre-Jiménez, MA, Iñigo-Gil, P, Tan, DX, García, JJ & Reiter, RJ 2016, 'Potential benefits of melatonin in organ transplantation: A review', Journal of Endocrinology, vol. 229, no. 3, pp. R129-R146. https://doi.org/10.1530/JOE-16-0117
Esteban-Zubero E, García-Gil FA, López-Pingarrón L, Alatorre-Jiménez MA, Iñigo-Gil P, Tan DX et al. Potential benefits of melatonin in organ transplantation: A review. Journal of Endocrinology. 2016;229(3):R129-R146. https://doi.org/10.1530/JOE-16-0117
Esteban-Zubero, Eduardo ; García-Gil, Francisco Agustín ; López-Pingarrón, Laura ; Alatorre-Jiménez, Moisés Alejandro ; Iñigo-Gil, Pablo ; Tan, Dun Xian ; García, José Joaquín ; Reiter, Russel J. / Potential benefits of melatonin in organ transplantation : A review. In: Journal of Endocrinology. 2016 ; Vol. 229, No. 3. pp. R129-R146.
@article{4db17e5157f04a65bf436aa64d0bd414,
title = "Potential benefits of melatonin in organ transplantation: A review",
abstract = "Organ transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemiareperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acid l-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.",
keywords = "Graft failure, Ischemia-reperfusion injury, Melatonin, Organ transplantation, Preservation fluids",
author = "Eduardo Esteban-Zubero and Garc{\'i}a-Gil, {Francisco Agust{\'i}n} and Laura L{\'o}pez-Pingarr{\'o}n and Alatorre-Jim{\'e}nez, {Mois{\'e}s Alejandro} and Pablo I{\~n}igo-Gil and Tan, {Dun Xian} and Garc{\'i}a, {Jos{\'e} Joaqu{\'i}n} and Reiter, {Russel J}",
year = "2016",
doi = "10.1530/JOE-16-0117",
language = "English (US)",
volume = "229",
pages = "R129--R146",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Potential benefits of melatonin in organ transplantation

T2 - A review

AU - Esteban-Zubero, Eduardo

AU - García-Gil, Francisco Agustín

AU - López-Pingarrón, Laura

AU - Alatorre-Jiménez, Moisés Alejandro

AU - Iñigo-Gil, Pablo

AU - Tan, Dun Xian

AU - García, José Joaquín

AU - Reiter, Russel J

PY - 2016

Y1 - 2016

N2 - Organ transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemiareperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acid l-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.

AB - Organ transplantation is a useful therapeutic tool for patients with end-stage organ failure; however, graft rejection is a major obstacle in terms of a successful treatment. Rejection is usually a consequence of a complex immunological and nonimmunological antigen-independent cascade of events, including free radical-mediated ischemiareperfusion injury (IRI). To reduce the frequency of this outcome, continuing improvements in the efficacy of antirejection drugs are a top priority to enhance the long-term survival of transplant recipients. Melatonin (N-acetyl-5-methoxytryptamine) is a powerful antioxidant and ant-inflammatory agent synthesized from the essential amino acid l-tryptophan; it is produced by the pineal gland as well as by many other organs including ovary, testes, bone marrow, gut, placenta, and liver. Melatonin has proven to be a potentially useful therapeutic tool in the reduction of graft rejection. Its benefits are based on its direct actions as a free radical scavenger as well as its indirect antioxidative actions in the stimulation of the cellular antioxidant defense system. Moreover, it has significant anti-inflammatory activity. Melatonin has been found to improve the beneficial effects of preservation fluids when they are enriched with the indoleamine. This article reviews the experimental evidence that melatonin is useful in reducing graft failure, especially in cardiac, bone, otolaryngology, ovarian, testicular, lung, pancreas, kidney, and liver transplantation.

KW - Graft failure

KW - Ischemia-reperfusion injury

KW - Melatonin

KW - Organ transplantation

KW - Preservation fluids

UR - http://www.scopus.com/inward/record.url?scp=84977635481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977635481&partnerID=8YFLogxK

U2 - 10.1530/JOE-16-0117

DO - 10.1530/JOE-16-0117

M3 - Review article

VL - 229

SP - R129-R146

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -